Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Q3 Revenue Rise

SAN FRANCISCO, Oct. 24 – Genaissance Pharmaceuticals on Wednesday posted third-quarter revenues of $1.1 million compared to $67,000 for the same quarter a year ago, the company announced.

“We have made considerable progress in the year since we completed our IPO,” Gualberto Ruano said in a statement. “Our technology is the gold standard for identifying gene variation, and our clinical development efforts have resulted in the initiation of the largest prospective genomics clinical trials ever conducted to correlate our proprietary gene markers with drug response.”

Genaissance, based in New Haven, Conn., recorded a net loss of $11.8 million for the third quarter of 2001 compared to a loss of $9.8 million for the year-ago quarter. Operating expenses rose to $15.6 million for the third quarter of this year, $12.6 million of which was R&D, from $11 million, $7.8 in R&D, in the same period in 2000.

As of September 30, 2001, Genaissance had $69 million in cash, cash equivalents, and marketable securities.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.